Lv5
1410 积分 2024-07-01 加入
Eloralintide, a selective amylin receptor agonist for the treatment of obesity: a 48-week phase 2, multicentre, double-blind, randomised, placebo-controlled trial
1天前
已完结
IL-6 inhibition with ziltivekimab in patients at high atherosclerotic risk (RESCUE): a double-blind, randomised, placebo-controlled, phase 2 trial
8天前
已完结
IL-6 inhibition with ziltivekimab in patients at high atherosclerotic risk (RESCUE): a double-blind, randomised, placebo-controlled, phase 2 trial
8天前
已完结
Inflammation and the pathogenesis of atherosclerosis
1个月前
已完结
Targeting cardiovascular inflammation: next steps in clinical translation
1个月前
已完结
Bempedoic Acid for Primary Prevention of Cardiovascular Events in Statin-Intolerant Patients
1个月前
已完结
Exploring the association between cumulative hs-CRP and all-cause mortality, with consideration of cardiometabolic mediators in middle-aged and elderly adults: Insights from observational study
1个月前
已完结
Randomized, Double-Blind, Phase 3 Trial of Triple Therapy With Dapagliflozin Add-on to Saxagliptin Plus Metformin in Type 2 Diabetes
1个月前
已完结
Efficacy and safety of dapagliflozin monotherapy in people with Type 2 diabetes: a randomized double‐blind placebo‐controlled 102‐week trial
1个月前
已完结
皖公网安备34019202002308
